This document discusses research and development (R&D) in biotechnology in Malaysia. It provides background on biotechnology and phases of Malaysia's biotechnology development plan from 2005-2020. Key areas that support R&D are discussed, including funding, expertise, intellectual property resources, and collaborations. The advantages of R&D in biotechnology are outlined as leading to industrial development, human capital development, strategic positioning and competitive advantages, engaging professional participation, and future economic growth through financial infrastructure development. The conclusion states that with Malaysia's biodiversity and support for R&D, biotechnology is expected to be a key driver of growth and generate significant revenue by 2020, and that investment in R&D is better than foreign technology

1. PRESENTED BY
NOOR HASVENDA
LILY SOPHIA
AHMAD SAUFE

2. OUR STAND

3. R&D?
 Creative work undertaken on a systematic basis in order to
increase the stock of knowledge, including knowledge of
man, culture and society, and the use of this stock of
knowledge to devise new applications"
 Techniques that involve science, technology and
mathematics.
 R&D has a special economic significance apart from its
conventional association with scientific and technological
development.
 R&D investment generally reflects a government's or
organization's willingness to forgo current operations or
profit to improve future performance or returns, and its
abilities to conduct research and development.

4. BIOTECHNOLOGY?
 Malaysia aspires to be a biotechnology hub and this is
clearly spelled out in the National Biotechnology
Policy that was launched on the 28th April 2005.
 The policy envisions that biotechnology will be a new
economic engine for Malaysia, enhancing the nation’s
prosperity and well-being.
 Among the type of biotechnology in Malaysia are
Agricultural Biotechnology, Food Biotechnology and
Medical Biotechnology.

5. FOREIGN TECHNOLOGY TRANSFER?
 The process of sharing of skills, knowledge,
technologies, methods of manufacturing, samples of
manufacturing and facilities among governments and
other institutions to ensure that scientific and
technological developments are accessible to a wider
range of users who can then further develop and exploit
the technology into new products, processes,
applications, materials or services. (Hargadon, Andrew,
2003)

6. PHASES OF
BIOTECHNOLOGY
PHASE 3 (2015 – 2020)
PHASE 2 (2010 – 2015)
PHASE 1 (2005-2010)

7. Initiatives under the National Biotechnology Policy are implemented within timeframe
of the thin timeframe of the Biotechnology Master Plan from 2005-2020

9. KEY AREAS
 R&D key indicator
 Funding
 Expertise/resources/agencies
 Intelectual property
 R&D Resources & Infrastucture

12. Funding
 Seed Fund
Seed or start-up fund with maximum amount of up to
RM2.5 million for bio-entrepreneurs at the beginning
stage of setting up business or companies
 R&D Matching Fund
Matching fund with maximum amount of RM1 million
to assist biotechnology companies execute research &
development (R&D) projects

13.  Malaysian Technology Development Corporation
(MTDC) MTDC offers 3 type of funds for
Biotechnology Industry which includes Non-ICT
Venture Fund, Technology Acquisition Fund (TAF) &
Commercialization of R&D Fund (CRDF)
 SME Bank
‘Program Usahawan Bioteknologi’ is one of the
initiative provided by SME Bank for small & medium
enterprises to accelerate their business growth in
Biotechnology Industry

14. Expertise/resources/agencies
 Malaysia Technology Development Corporation
 BIOTECH CORP
 Malaysia Biotechnology Information Centre (MBIC)
 Malaysian Industrial Development Authority (MIDA)
 Forest Research Institute of Malaysia (FRIM)
 MARDI
 MPOB
 MRB
 Higher Learning Institution: Apex University

15. Intelectual property
 SIRIM BHD
 Full ranger of IP services: patent information services,
opinion writing and patent drafting.
 Rapid prototyping services
 Product testing and certification
 Technology incubator services

17. Collaborations
 Massachusetts Institute of Technology (MIT), USA
 National Cancer Institute, USA
 Medichem Research of Lemont, Illinois, USA
 Nimura Genetic Solutions, Japan
 Functional Food Creation Research Institute Co. Ltd.,
Japan
 Cambridge University, UK
 Centre for Genetic Engineering and Biotechnology,
Cuba (CIBG)

18. Advantage of R&D in Biotechnology
Biotechnology Industrial
Development
Lead to Human Capital
Development
Financial
Infrastructure
Development that will
lead to future Strategic positioning
economic growth that contribute to
competitive
advantages
Engaging professional
participation

19. ADVANTAGE OF R&D IN BIOTECHNOLOGY
 Biotechnology Industrial Development
-Transform and enhance the value creation of the sector.
-Able to bring together multidisciplinary research teams to
accommodate co-ordinate research and commercialization
initiatives.
-It also accelerates technology development via strategic acquisitions.
 Lead to Human Capital Development
-Potentially building our nation’s biotech human resource capability and
talent that is in line with market needs through special schemes,
programmes and training.
 Strategic positioning that contribute to competitive advantages
-Ability to establish a global marketing strategy in the effort to build
recognition for Malaysian biotech and benchmark progress.
-Establish our country as a centre for Contract Research Organizations
and Contract Manufacturing Organizations

20.  Engaging professional participation
Broadening the scope of R&D exploration by engaging
commitment of a dedicated and professional agencies that
overseeing the development of Malaysia’s biotech industry. This
will increase the opportunities for a high quality result.
 Financial Infrastructure Development that will lead to
future economic growth
New investment area in R&D by stimulating funding and
incentives to promote committed participation by the private
sector as well as government-linked companies.

21. CONCLUSION
 Malaysia has identified biotechnology to be the new engine
of growth for the country and with its rich biodiversity and
cost-competitive skilled labor markets combined with good
transportation and ICT infrastructure as well as strong
support in R&D.
 Biotechnology as a key driver of growth for Malaysia and is
expected to generate RM270 billion in revenue for the
country by 2020.
 With adequate funding,expertise,R&D Resources &
Infrastucture,we believe that investment in R&D is better
option than having a foreign technology transfer.

22. Q & A SESSION